Difference between revisions of "Histrelin (Vantas)"
Jump to navigation
Jump to search
m (→Also known as) |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.<ref name="insert">[ | + | Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.<ref name="insert">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021732s015lbl.pdf Histrelin (Vantas) package insert]</ref><ref>[[:File:Histrelin.pdf | Histrelin (Vantas) package insert (locally hosted backup)]]</ref><ref>[http://www.vantasimplant.com/ Vantas implant manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *10 | + | *2004-10-12: Initial approval in the palliative treatment of advanced [[prostate cancer]]. ''(Based on Schlegel 2006)'' |
| − | + | ==History of changes in Health Canada indication== | |
| + | *2006-03-10: Initial notice of compliance (unclear details) | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021732s015lbl.pdf Histrelin (Vantas) package insert]<ref name="insert"></ref> |
==Also known as== | ==Also known as== | ||
| Line 30: | Line 31: | ||
[[Category:FDA approved in 2004]] | [[Category:FDA approved in 2004]] | ||
| + | [[Category:Health Canada approved in 2006]] | ||
Latest revision as of 01:03, 29 June 2024
General information
Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.[1][2][3]
Route: SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication
- 2004-10-12: Initial approval in the palliative treatment of advanced prostate cancer. (Based on Schlegel 2006)
History of changes in Health Canada indication
- 2006-03-10: Initial notice of compliance (unclear details)
Patient drug information
Also known as
- Generic name: histrelin acetate
- Brand names: Supprelin, Vantas